Clinical Features and Detection of Congenital Hypothyroidism
Clinical Features
Most newborns with congenital hypothyroidism appear clinically normal at birth, making biochemical screening essential rather than relying on clinical diagnosis alone 1, 2. The clinical signs are typically subtle and nonspecific in the neonatal period.
Key Clinical Manifestations
When present, the following features are most discriminatory:
- Feeding difficulties - poor feeding, not waking for feeds, slow feeding
- Constipation
- Dry skin
- Umbilical hernia
- Enlarged posterior fontanelle (persistence beyond expected closure)
- Prolonged neonatal jaundice (>2 weeks)
- Lethargy and hypotonia
- Macroglossia
- Cold extremities
- Coarse/puffy facial features
Important Clinical Caveat
Even using structured clinical scoring systems (like the Quebec neonatal hypothyroid index), only 50% of hypothyroid infants score above the threshold of 2 points 2. This underscores why clinical examination alone is inadequate for diagnosis and why universal biochemical screening is mandatory 1, 3.
Severity Assessment
CH severity should be assessed using multiple parameters simultaneously 1:
Biochemical severity (based on serum FT4 at diagnosis):
- Severe: FT4 <5 pmol/L
- Moderate: FT4 5-10 pmol/L
- Mild: FT4 10-15 pmol/L
Skeletal maturation markers:
- Absent distal femoral and/or proximal tibial epiphyses on knee X-ray indicates severe intrauterine hypothyroidism and correlates with worse neurodevelopmental outcomes 1
Associated findings requiring examination 1:
- All neonates with elevated TSH must be carefully examined for congenital malformations, particularly cardiac defects, and dysmorphic features - these associations are common enough to warrant systematic evaluation
Detection Methods
Newborn Screening Strategy
Universal neonatal screening using dried blood spot (DBS) testing is the cornerstone of CH detection, optimally performed between 2-5 days of age 1, 3.
Screening Approaches
Different programs use:
- Primary TSH measurement (most common in Europe)
- Primary T4 with backup TSH (common in North America)
- Combined TSH and T4
High-Risk Populations Requiring Second Screen
A second screening test should be performed for 1:
- Preterm infants
- Low birth weight (<2500g) and very low birth weight infants
- Ill neonates in NICU
- Specimens collected within first 24 hours of life
- Multiple births, especially same-sex twins
Diagnostic Algorithm After Abnormal Screen
Immediate Action Thresholds
If capillary TSH ≥40 mU/L whole blood: Start treatment immediately after obtaining venous sample, without waiting for confirmatory results 1
If capillary TSH <40 mU/L whole blood: May wait for venous results, but these must be available within 24 hours 1
Confirmatory Venous Testing
Obtain serum TSH and free T4 (or total T4) using age-specific reference ranges - thyroid function undergoes dynamic changes in the first weeks of life 1, 3.
Treatment Initiation Criteria (Venous Results)
Start treatment immediately if:
- Venous FT4 is below age-specific norms (regardless of TSH level) 1
- Venous TSH ≥20 mU/L (even if FT4 is normal) 1
For TSH 6-20 mU/L beyond 21 days of age with normal FT4:
- Perform diagnostic imaging (thyroid ultrasound and/or scintigraphy)
- Discuss with family: either start treatment immediately with plan to retest off treatment later, OR retest in 2 weeks without treatment
- If TSH remains elevated >3-4 weeks, initiate treatment 1
Diagnostic Imaging
Thyroid imaging should be performed using radioisotope scanning (scintigraphy) with or without perchlorate discharge test, and/or ultrasonography 1.
Critical principle: Imaging must never delay treatment initiation 1.
Imaging Purposes
- Determine etiology (thyroid dysgenesis vs. dyshormonogenesis)
- Assess gland location (ectopic vs. eutopic)
- Identify athyreosis, hypoplasia, or goiter
- Guide prognosis and genetic counseling
Serum thyroglobulin below detection threshold strongly suggests athyreosis or complete thyroglobulin synthesis defect 1.
Communication Protocol
Abnormal screening results must be communicated by experienced personnel (screening laboratory staff or pediatric endocrine team) via telephone or in person 1.
The infant should be seen for clinical assessment and venous testing on the day of referral or next day at latest 1.
Parents should be shown how to administer the first levothyroxine dose by the clinician or pharmacist 1.
Important: When the child reaches school age, educators and teachers should NOT be informed about the CH diagnosis to avoid stigmatization and labeling 1.
Special Considerations
Delayed TSH Rise
Some infants display delayed TSH elevation despite normal initial screening - this pattern may be more common and severe than previously recognized, particularly in preterm and NICU infants 5. This justifies the second screening recommendation for high-risk populations.
Central (Secondary) Hypothyroidism
While much less common than primary CH, central hypothyroidism can be equally severe. TSH-based screening will miss these cases; T4-based or combined screening strategies are needed for detection 5.